Correlation of CA-simple sequence repeat polymorphism of epidermal growth factor receptor gene with clinical outcome of patients with advanced non-small cell lung cancer after treatment with epidermal growth factor receptor tyrosine kinase inhibitors
10.3781/j.issn.1000-7431.2011.07.011
- Author:
Song-Wen ZHOU
1
Author Information
1. Department of Medical Oncology
- Publication Type:Journal Article
- From:
Tumor
2011;31(7):633-637
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the correlation of CA-simple sequence repeat (SSR) polymorphismof epidermal growth factor receptor (EGFR ) gene with the clinical outcome of patients with advancednon-small cell lung cancer (NSCLC) after treatment with epidermal growth factor receptor tyrosinekinase inhibitors (EGFR-TKIs). Methods: The clinical outcome and the survival of 101 patients withadvanced NSCLC after treatment with EGFR-TKIs were measured. CA-SSR polymorphisim of EGFR intron1 from peripheral blood cells of NSCLC patients was detected by PCR and direct DNA sequencing. Thecorrelations of CA-SSR polymorphisim with the clinical outcome and the survival of NSCLC patientsafter treatment with EGFR-TKIs were analyzed. Results: Twenty-four patients reached a partial response(23.8%), 46 patients reached a stable disease (45.5%), and 70 patients reached a clinical benefit (69.3%).Median survival time (MST) in female or adenocarcinoma patients was longer than that in male or non-adenocarcinoma patients (P<0.05). Allele (CA)20 was the most frequent allele (68.7%, 68/99) in CA-SSR.Progression-free survival (PFS) in patients with short CA-SSR was longer than that in patients with long CA-SSR (P<0.039). The MSTs of patients with short CA-SSR and long CA-SSR were 15.7 and 14.4 months, respectively, and the difference in MST was not significant (P = 0.691). Conclusion: The MST of female or adenocarcinoma patients with NSCLC as well as the PSF of patients with short CA-SSR can be prolonged after treatment with EGFR-TKIs. Copyright© 2011 by Tumor.
